A Manhattan-based biopharmaceutical firm has announced positive topline data from its phase 2 trial of a novel formulation of intranasal racemic ketamine for acute suicidal ideation and behavior in adults with major depressive disorder.
According to Seelos Therapeutics, the double-blind, placebo-controlled cohort of its ongoing study of SLS-002 compared with placebo demonstrated early and persistent reductions in symptoms of depression for its 147 participants, as assessed by the Montgomery Åsberg Depression Rating Scale (MADRS).
The company acknowledged the study did not meet the